#DESTINY-Breast05 trial #GBG103 at #ESMO2025: T-DXd as a potential new #SOC?

The phase III study demonstrated statistically significant and clinically meaningful improvement in #IDFS #DFS with #T-DXd vs #T-DM1 in pts with high-risk #HER2-positive eBC who had residual invasive disease.